Berg Capital Partners is a capital markets advisory and investment firm that helps leading edge healthcare companies to source the critical investment funds required to transform their vision from concept to reality. At Berg Capital Partners, we are dedicated to collaborating closely with our healthcare clients, as we aim to establish ourselves as trusted partners throughout their capital raising journey. Our mission is to assist our clients in unlocking the full potential of their innovations, thereby making a profound impact on the well-being of countless patients worldwide. Berg Capital Partners is proud to announce our partnership with OncoHost in raising $25 million to support the commercial advancement of PROphet, a precision oncology platform revolutionizing the standard of care for non-small cell lung cancer diagnostics. OncoHost's groundbreaking approach, leveraging advanced technologies and personalized insights, aligns seamlessly with our vision for advancing breakthroughs in the oncology sector. As a forward-thinking investment firm, we recognize the tremendous clinical utility of OncoHost's PROphet platform in substantially improving patient treatment. This partnership signifies a shared commitment to pushing the boundaries of what is possible in the fight against cancer. OncoHost's dedication to tailoring patient treatments based on individual patient characteristics, coupled with Kindling Investment Partners' strategic support, positions the company for continued success and growth. We are excited about the impact this collaboration will have on advancing OncoHost's mission to transform cancer care through precision medicine. Our investment signifies not only our confidence in OncoHost's capabilities but also our belief in the potential for positive, lasting change in the lives of cancer patients. We look forward to a fruitful partnership with OncoHost and anticipate exciting developments as we collectively contribute to shaping the future of personalized cancer treatment.